Reply: Lecanemab: turning point, or status quo? An ethics perspective
Brain
.
2023 Sep 1;146(9):e73.
doi: 10.1093/brain/awad102.
Authors
John Hardy
1
2
3
,
Catherine Mummery
2
Affiliations
1
Reta Lilla Weston Research Laboratories, UCL Institute of Neurology, London WC1N 3BG, UK.
2
Department of Neurodegenerative Disease, UCL Institute of Neurology, London WC1N 3BG, UK.
3
Dementia Research Institute, UCL Institute of Neurology, London WC1N 3BG, UK.
PMID:
36995943
PMCID:
PMC10473552
DOI:
10.1093/brain/awad102
No abstract available
Publication types
Letter
Comment
MeSH terms
Alzheimer Disease*
Amyloidogenic Proteins
Decision Making
Humans
Substances
lecanemab
Amyloidogenic Proteins